Newsfile·2025-12-03 04:10Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a class action lawsuit related to securities purchased between November 4, 2024, and October 3, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [4]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].